[go: up one dir, main page]

MX2016010852A - Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. - Google Patents

Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.

Info

Publication number
MX2016010852A
MX2016010852A MX2016010852A MX2016010852A MX2016010852A MX 2016010852 A MX2016010852 A MX 2016010852A MX 2016010852 A MX2016010852 A MX 2016010852A MX 2016010852 A MX2016010852 A MX 2016010852A MX 2016010852 A MX2016010852 A MX 2016010852A
Authority
MX
Mexico
Prior art keywords
human pai
antibody
amino acid
pai
new anti
Prior art date
Application number
MX2016010852A
Other languages
English (en)
Inventor
Tanaka Hirotsugu
Yoshino Masayasu
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016010852A publication Critical patent/MX2016010852A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Problema: Proveer un anticuerpo anti-PAI-1 de humano para prevenir o tratar fibrosis pulmonar mediante unión a PAI-1 activo de humano e inhibición de los efectos mediados por PAI-1 activo de humano. Solución al problema: Los presentes inventores han investigado los anticuerpos anti-PAI-1 y en consecuencia han provisto un anticuerpo anti-PAI-1 de humano que comprende una región variable de la cadena pesada que consiste de la secuencia de aminoácido de los números de aminoácido 1 a 118 de SEQ ID NO: 2 y una región variable de la cadena ligera que consiste de la secuencia de aminoácido de los números de aminoácido 1 a 108 de SEQ ID NO: 4.
MX2016010852A 2014-02-21 2015-02-20 Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. MX2016010852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014031319 2014-02-21
PCT/JP2015/054704 WO2015125904A1 (ja) 2014-02-21 2015-02-20 新規抗ヒトｐａｉ－１抗体

Publications (1)

Publication Number Publication Date
MX2016010852A true MX2016010852A (es) 2016-10-26

Family

ID=53878402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010852A MX2016010852A (es) 2014-02-21 2015-02-20 Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.

Country Status (14)

Country Link
US (1) US9803024B2 (es)
EP (1) EP3109320B1 (es)
JP (1) JP6512213B2 (es)
KR (1) KR20160124840A (es)
CN (1) CN106029884B (es)
BR (1) BR112016019332A2 (es)
CA (1) CA2939897A1 (es)
ES (1) ES2726915T3 (es)
MX (1) MX2016010852A (es)
PL (1) PL3109320T3 (es)
PT (1) PT3109320T (es)
RU (1) RU2016137486A (es)
TR (1) TR201907379T4 (es)
WO (1) WO2015125904A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121358A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法
WO2018107700A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗病理性肾组织损伤的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
WO2021066062A1 (ja) 2019-09-30 2021-04-08 株式会社レナサイエンス 免疫チェックポイント分子の発現抑制剤
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742997A1 (de) * 1987-12-18 1989-06-29 Behringwerke Ag Peptide, verfahren zu ihrer herstellung, ihre verwendung zur gewinnung von antikoerpern sowie deren verwendung zur blockierung der pai-1-aktivitaet menschlichen blutes
AU2002216847A1 (en) * 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
EP2198055A4 (en) * 2007-09-07 2012-04-18 Cisthera Inc HUMANIZED PAI-1 ANTIBODIES
CN101654405A (zh) * 2008-08-19 2010-02-24 信谊药厂 抗凝化合物、组合物及其用途
US20100254979A1 (en) 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
EP2566514A4 (en) 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES

Also Published As

Publication number Publication date
RU2016137486A (ru) 2018-03-22
US20160369008A1 (en) 2016-12-22
JPWO2015125904A1 (ja) 2017-03-30
EP3109320A1 (en) 2016-12-28
US9803024B2 (en) 2017-10-31
JP6512213B2 (ja) 2019-05-15
PT3109320T (pt) 2019-06-06
CN106029884B (zh) 2019-06-25
KR20160124840A (ko) 2016-10-28
CA2939897A1 (en) 2015-08-27
BR112016019332A2 (pt) 2017-10-10
EP3109320A4 (en) 2017-09-20
TR201907379T4 (tr) 2019-06-21
ES2726915T3 (es) 2019-10-10
RU2016137486A3 (es) 2018-07-27
CN106029884A (zh) 2016-10-12
PL3109320T3 (pl) 2019-08-30
WO2015125904A1 (ja) 2015-08-27
EP3109320B1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
AU2018260800A1 (en) Hepcidin analogues and uses therof
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
NZ737796A (en) Anti-tau antibodies and methods of use
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MY198942A (en) Anti-tau antibodies and methods of use
IL268160A (en) Anti-TNF antibodies, preparations and methods for the treatment of active ankylosing spondylitis
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
NZ630542A (en) Methods of treating a tauopathy
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
SG10201907901XA (en) Antibodies, uses & methods
MX2016010852A (es) Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX384640B (es) ANTICUERPO IGß ANTIHUMANO NOVEDOSO.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
PH12016502569A1 (en) Anti-il4-il13 bispecific antibodies
MY184164A (en) Novel anti-human ngf antibody fab fragment
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.